SEC Comment Letter 0000000000-26-004625 to Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc.
Date: May 6, 2026 · CIK: 0001892500 · Accession: 0000000000-26-004625
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295455
Letter
May 6, 2026 Dr. Adi Zuloff-Shani Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re: Clearmind Medicine Inc. Registration Statement on Form F-3 Filed April 30, 2026 File No. 333-295455 Dear Dr. Adi Zuloff-Shani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Huberman, Esq.
Show Raw Text
May 6, 2026 Dr. Adi Zuloff-Shani Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re: Clearmind Medicine Inc. Registration Statement on Form F-3 Filed April 30, 2026 File No. 333-295455 Dear Dr. Adi Zuloff-Shani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Huberman, Esq.